OSLO, Norway, Oct. 9, 2019 /PRNewswire/ — Targovax ASA (OSE: TRVX), announces that clinical data on the company’s lead product candidate ONCOS-102, a genetically modified oncolytic adenovirus which has been engineered to selectively infect and replicate in cancer cells, will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting being held November 6-10, 2019, in Maryland, USA.
| Title: | A pilot study of engineered adenovirus ONCOS-102 in combination with pembrolizumab in checkpoint inhibitor refractory advanced or unresectable melanoma |
| Authors: | Alexander N. Shoushtari, MD; Anthony J. Olszanski, MD, RPh; Thomas J. Hornyak, MD; Jedd D. Wolchok, MD, PhD; Sylvia Vetrhus; Karianne Risberg Handeland; Lukasz Kuryk, PhD; Magnus Jaderberg, MD; |
| Date: | 9 November 2019 |
| Time: | 5:30 pm – 5:45 pm |
| Presenter: | Dr. Alexander Shoushtari, Principal Investigator, MSKCC, NYC |
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47-922-61-624
Email: renate.birkeli@targovax.com
Media and IR enquires:
Andreas Tinglum – Corporate Communications (Norway)
Phone: +47-9300-1773
Email: andreas.tinglum@corpcom.no
This information was brought to you by Cision http://news.cision.com
SOURCE Targovax
WASHINGTON — Today, the U.S. Department of the Treasury’s Office of Foreign Assets Control (OFAC)…
WASHINGTON – Today, the U.S. Department of the Treasury and Internal Revenue Service (IRS) outlined…
WASHINGTON—Acting Senior Deputy Comptroller and Chief Counsel Ted Dowd today testified on the Office of…
The Committee convened in a closed session at the Department of the Treasury at 9:00…
WASHINGTON — Today, the Department of the Treasury is taking action to further degrade Russia’s…
WASHINGTON – The final results from the annual survey of foreign portfolio holdings of U.S. securities at…